Kornimate/medical-research-clean huggingface dataset:
a head-to-head comparative study of 18f-psma-1007 pet/ct and 18f-fdg pet/ct imaging in multiple myeloma

Conditions: Multiple Myeloma

Summary: multiple myeloma (mm) is the second most common hematological malignancy and is still incurable. positron emission tomography/computed tomography (pet/ct) has been used to diagnose, assess treatment response, and predict prognosis in mm. 18f-fluorodeoxyglucose (fdg) is the most widely used radiotracer, but there is heterogeneous uptake in mm, that is, uptake is negative in some myeloma cells. there are currently reports of cases with strong uptake of prostate-specific membrane antigen (psma) pet/ct in mm. therefore, this preliminary study was designed to compare the imaging results of 18f-psma-1007 pet/ct and 18f-fdg pet/ct, and to evaluate the additional value of 18f-psma-1007 pet/ct to 18f-fdg pet/ct in mm.

18f-fluorodeoxyglucose (fdg) pet/ct can identify bone lesions, assess disease burden, and detect extramedullary lesions in multiple myeloma(mm), but due to mm is a complex and heterogeneous disease , 18f-fdg pet/ct has heterogeneous uptake in mm bone lesions, resulting in false negative results in the diagnosis of mm bone disease, then affecting the diagnosis, staging and evaluation of the response to treatment of mm. prostate-specific membrane antigen (psma) is a specific membrane-bound glycoprotein, recently high uptake in psma pet/ct in mm bone lesions has been published in case reports, thus psma pet ct imaging may have potential value for multiple myeloma. there are no head-to-head studies comparing 18f-psma-1007 pet/ct with 18f-fdg pet/ct in multiple myeloma. therefore, this study intends to compare the detection rate of lesions by 18f-psma-1007 pet/ct and 18f-fdg pet/ct in mm , and to evaluate the additional value of 18f-psma-1007 pet/ct to 18f-fdg pet/ct in multiple myeloma.

Eligibility criteria:
inclusion criteria: * confirmed untreated or relapsed multiple myeloma patients; * 18f-psma-1007 and 18f-fdg pet/ct within one week; * signed written consent; * no combined other malignant tumors. exclusion criteria: * suffered from arthritis or combined with other malignant tumors; * received myeloma-related therapy within 3 months before pet/ct imaging * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Keywords: multiple myeloma prostate specific membrane antigen fluorodeoxyglucose positron emission tomography/computed tomography
predictive score for neonatal mortality for women with premature rupture of membranes between 22 and 28 weeks of gestation

Conditions: Perinatal Mortality; Premature Rupture of Fetal Membranes

Summary: pretern premature rupture of the membranes (pprom) remains the leading cause of preterm deliveries and neonatal mortality and morbidity. pprom is defined as rupture of the fetal membranes prior to 37 weeks' gestation. pprom complicates 2-4% of all pregnancies and accounts for approximately 30 % of preterm births. the etiology of pprom remains elusive. pprom is one of the main causes of prematurity and its complications, such as newborn respiratory distress syndrome, neonatal sepsis, necrotizing enterocolitis, intraventricular hemorrhage, perventricular leucomalacia, varying degrees of lung hypoplasia and bronchopulmonary dysplasia. all these factors contribute greatly to an increase in neonatal morbidity and mortality management of pprom followed actual guidelines. conservative management to prolong a pregnancy is a classical approach to treat pprom before 34 weeks' gestation in association with antibiotic therapy and corticosteroids. maternal and neonatal data were collected from maternal and newborns medical records.


Eligibility criteria:
inclusion criteria: * women with pprom between 22 weeks and 27 weeks and 6 days are eligible for this study exclusion criteria: * therapeutic abortion / terminaison of pregnancy * intra uterine demise * active labor with cervical dilatation of 3 cm with regular contractions. * triplet pregnancies

Keywords: predictive score
diabetic under 70 (diabetics below 70)

Conditions: Diabetes; Hyperlipidemia; Atherosclerosis

Summary: a screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus coronary heart disease) who already receive cholesterol-lowering therapy. lipid profile and rate of patients who are treated to target (which is \<70mg/dl for such patients with very high risk) are screened. the doctors therapy decisions after the screening will be documented and 8-10 weeks later the lipid profile of each patient will be evaluated again. our aim is to evaluate dosing habits, to evaluate how many patients are treated to their ldl-c target and to underline the importance of treating patients to their cholesterol targets.


Eligibility criteria:
inclusion criteria: * diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, pavk, etc.) who already receive cholesterol-lowering therapy exclusion criteria: * diabetics w/o cvd; diabetics who do not receive cholesterol-lowering therapy

Keywords: hyperlipidemia diabetics nis diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, pavk, etc.)
biomarkers of common eye diseases

Conditions: Uveitis; Diabetic Retinopathy; Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy; VKH Syndrome; Behçet Disease

Summary: to identify biomarkers of common eye diseases based on single-cell sequencing technologies using pbmc samples. these diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal vasculopathy. our study may provide new insight into the underlying mechanisms, and reveal novel predictors and intervention targets for the diagnosis, prognosis and treatment of these diseases.

the pathogenesis of common eye diseases such as uveitis (including behcet's disease (bd) and vogt-koyanagi-harada disease (vkh)), diabetic retinopathy (dr), age-related macular degeneration (amd) and polypoid choroidal vasculopathy (pcv) remains unknown. although immunosuppressants, anti-vascular endothelial growth factor (vegf) agents, and pars plana vitrectomy (ppv) have been widely used for treatment, the current therapeutic options are limited. in addition, there is a lack of biomarkers to indicate the prognosis and treatment response of these diseases. the aim of this study is to identify biomarkers and to provide a new target for individualized diagnosis and treatment of common eye diseases based on single cell sequencing technology.

Eligibility criteria:
inclusion criteria for patients: 1. age over 18 (including 18 years old); 2. clinically diagnosed as diabetic retinopathy (dr), uveitis (vkh or bd) , age-related macular degeneration (amd) , or polypoid choroidal vasculopathy (pcv) exclusion criteria for patients with retinal diseases: 1. have received more than 2 intravitreal injections of anti-vegf drugs because of retinal or choroidal neovascularization and macular edema; 2. patients with stable condition after having undergone panretinal laser photocoagulation and pars plana vitrectomy (ppv); 3. there are other serious systemic diseases of the body, such as history of chronic kidney disease requiring dialysis or a kidney transplant, unstable blood pressure, cardiovascular disease, tumors, etc; 4. patients who are pregnant or nursing
fluid management strategies on blood loss in liver transplantation

Conditions: Liver Transplant

Summary: during liver transplantation, due to the complexity of the operation and abnormal coagulation function, there may be a large amount of bleeding and corresponding blood transfusion. excessive blood transfusion will increase pulmonary complications and affect the prognosis. infusion management to reduce bleeding is a very important issue in liver transplant surgery. restrictive infusion management can effectively reduce the amount of bleeding in liver transplantation, but it remains unclear whether it will cause sequelae in other major organs. the investigators plan to study different infusion goals and strategies in liver transplant surgery using a randomized group model, using the picco (pulse contour cardiac output) cardiopulmonary volume monitor, and setting the stroke volume variation (svv) as the macroscopic circulation.the purpose of this study was to divide it into restrictive and liberal groups to explore the impact on liver transplantation bleeding volume and inflammatory response as well as postoperative lung and renal function, and to collect statistics on clinical care and postoperative sequelae (pulmonary liver, renal function impairment, etc.) in order to develop the most appropriate infusion management strategy in liver transplantation.


Eligibility criteria:
inclusion criteria: * end stage liver disease * age between 18y/o to 75 y/o * expected to recieve to receive liver transplantation exclusion criteria: * arrythmia

Keywords: fluid management blood loss
pcos indirect and intangible economic burden

Conditions: Polycystic Ovary Syndrome

Summary: the primary purpose of the pcos indirect and intangible economic buren study is to estimate the economic costs of having pcos in terms of quality of life and work productivity. the population will include individuals with a clinical diagnosis of pcos, individuals self-diagnosed with pcos, individuals with symptoms of pcos (e.g., hirsutism, irregular menstrual cycles), and demographic-matched controls without pcos. this study is a sub-study of the pcos challenge study.


Eligibility criteria:
inclusion criteria: * diagnosed with pcos by a health professional, self-diagnosed with pcos or individuals with pcos symptoms * willing to sign the consent form * able to understand the registry surveys or what is being asked exclusion criteria: * unable to understand the surveys or what is being asked * unwilling to sign the consent form

Keywords: pcos polycystic ovary syndrome polycystic ovarian syndrome stein leventhal syndrome
impact of non-surgical periodontal therapy in the management of plaque psoriasis.

Conditions: Psoriasis Vulgaris; Psoriasis; Periodontitis

Summary: both periodontitis and plaque psoriasis are non communicable chronic inflammatory diseases. they share genetic polymorphysms (il-1, il-6 e tnfalfa) and risk factors (smoking, diabetes, obesity), as well as a great resemblance in terms of pathophysiological pathways. in fact, they are both characterized by an hyperactivation of the innate immune response which induces an excessive production of cytokines such as il-17/tnfalfa. while non-surgical periodontal therapy consists in the mechanical removal of supra and subgingival calculus, psoriasis treatment involves the administration of either systemic or biologic drugs. evidence is scarce regarding the effectiveness of non-surgical periodontal therapy in ameliorating the clinical outcomes of plaque psoriasis. the biological plausibility relies on the important reduction of systemic inflammation caused by periodontal treatment, which could ameliorate psoriasis phenotype.


Eligibility criteria:
inclusion criteria: * diagnosis of plaque psoriasis; * diagnosis of untreated periodontitis; * presence of at least 20 teeth; * age between 18 and 70 years; * ability and willingness to give informed consent. exclusion criteria: * inability of unwillingness to give informed consent; * patients undergoing periodontal treatment within the last 6 months; * patients undergoing immunosuppressive treatments for other systemic diseases; * pregnancy or lactation; * pts undergoing antibiotic therapy.
effect of angiotensin-neprilysin inhibition (arni) on prognosis of chronic heart failure

Conditions: Chronic Heart Failure

Summary: this study is a randomized controlled multicenter clinical trial, in which about 340 patients with newly diagnosed or prior diagnosed chronic heart will be recruited. patients will be randomly divided into angiotensin-neprilysin inhibition (arni) group and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (acei/arb) group. all-cause death, cardiac death and re-hospitalization due to heart failure will be evaluated in 1, 3, 6, 12 months after recruitment.

chronic heart failure is associated with poor prognosis in cardiac patients, although systemic effective drugs has been applied in these patients. european society of cardiology (esc) has recommended arni sacubitril/valsartan as first-line drugs in replacement of acei (i, b) in 2016 for these patients. while american college of cardiology and the american heart association (acc/aha) made a first-line recommendation that patients with heart failure due to reduced ejection fraction (hfref) could be administrated arni directly. hence, we apply this trial to find if arni could replace acei/arb to provide insights for better treatment of chronic heart failure in china. this study is a randomized controlled multicenter clinical trial, in which about 340 patients with newly diagnosed or prior diagnosed chronic heart will be recruited. patients will be randomly divided into angiotensin-neprilysin inhibition (arni) group and acei/arb group. all-cause death, cardiac death and re-hospitalization due to heart failure will be evaluated in 1, 3, 6, 12 months after recruitment. other safety assessment including left ventricular ejection fraction (lvef), 6 minutes walk test will be followed up as well.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * hfref, defined as lvef≤40% and new york heart association (nyha) class ≥ ii. * plasma nt-probnp ≥ 600 pg/ml, or nt-probnp ≥ 400 pg/ml if patients have been hospitalized for heart failure in 12 months. * if patients have been taking acei/arb at recruitment, a stable dose equivalent to at least 10mg/day of enalapril will be required. * volunteer for the study and sign the informed consent. exclusion criteria: * symptomatic hypotension, systolic blood pressure \< 95 mmhg at baseline. * egfr \< 30 ml(/min\*1.73m2) at baseline. * serum potassium \> 5.4 mmol/l at baseline. * contraindication of acei or arb.

Keywords: shakurba valsartan heart failure acei/arb
the vesalio neva stent retriever study for treatment of large vessel occlusion strokes

Conditions: Acute Ischemic Stroke

Summary: a prospective, open label, single-arm 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the neva stent retrievers.

this is a prospective, open label, multi-center, single-arm trial designed to assess the safety, performance and efficacy of the neva stent retriever in the treatment of large vessel occlusion strokes. up to 150 subjects at up 20 sites will participate in the study.

Eligibility criteria:
inclusion criteria: 1. clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke, and subject belongs to one of the following subgroups: 1.1. subject has failed iv t-pa therapy 1.2. subject is contraindicated for iv t-pa administration 1.3. iv-tpa given within 3 hours of symptom onset 2. age ≥18 and less than equal to 85 3. nihss score ≥ 8 and ≤ 25 4. prestroke mrs score of ≤ 1 5. intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (m1/m2), anterior cerebral artery (aca), posterior cerebral artery (pca), basilar artery, or vertebral artery demonstrated with dsa. 6. thrombectomy procedure can be initiated within 8 hours from symptom onset (defined as time last known well \[tlkw\]) and at least one neva pass occurring within 8 hours 7. imaging inclusion criteria: 7.1. non-contrast ct selection (if ct perfusion or mri not utilized): aspects 6-10 , or 7.2. ct perfusion core ≤50 cc, or 7.3. mri dwi core ≤50 cc 8. subject or (legal) representative or independent physician (if approved by site's regional ethics committee, see site's informed consent form) is able and willing to give informed consent prior to the interventions. exclusion criteria: 1. pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. aricept). 2. cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre-treatment pulmonary aspiration. 3. clinical symptoms suggestive of bilateral stroke or stroke in multiple territories. 4. cerebral vasculitis 5. history of severe allergy to contrast medium. 6. known allergy to neva materials (nitinol, stainless steel); 7. suspicion of aortic dissection, septic embolus, or bacterial endocarditis 8. systemic infection 9. significant mass effect with midline shift 10. evidence of intracranial tumor (except small meningioma \[≤ 3cm\]) 11. any ct or mri evidence of acute hemorrhage products on presentation 12. inability to deploy neva device for at least one pass for any other reason 13. life expectancy less than 6 months 14. any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed. 15. active malignancy 16. stenosis or occlusion in a proximal vessel requiring treatment or preventing access to the thrombus.
gm-csf for reversal of immunoparalysis in pediatric sepsis-induced mods

Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome

Summary: the grace-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug gm-csf vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (mods) who have immunoparalysis with mild to moderate inflammation.

the grace-2 study is a is a prospective, multi-center, double-blind, randomized controlled trial of the drug gm-csf vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (mods) who have immunoparalysis with mild to moderate inflammation. eligible subjects will undergo centralized immunophenotyping on mods day 2. those who are found to have immunoparalysis (a whole blood lps-induced tnf-alpha production capacity \< 200 pg/ml) with mild to moderate inflammation (serum ferritin level \< 2000 ng/ml) will be randomized to receive intravenous (iv) gm-csf at a dose of 125 mcg/m2/day x 7 days or placebo. the primary outcome variable is the cumulative 28-day pediatric logistic organ dysfunction (pelod)-2 score. secondary outcomes include measures of health-related quality of life and function status at 3 months from randomization.

Eligibility criteria:
inclusion criteria: * ≥ 40 weeks corrected gestational age to \< 18 years; and * admission to the picu or cicu; and * onset of ≥ 2 new organ dysfunctions within the last 3 calendar days (compared to pre-sepsis baseline) as measured by the modified proulx criteria; and * documented or suspected infection as the mods inciting event. exclusion criteria: * weight \<3kg; or * limitation of care order at the time of screening; or * patients at high likelihood of progression to brain death in opinion of the clinical team; or * moribund condition in which the patient is unlikely to survive the next 48 hours in opinion of the clinical team; or * history of myeloid leukemia, myelodysplasia, or autoimmune thrombocytopenia; or * current or prior diagnosis of hemophagocytic lymphohistiocytosis or macrophage activation syndrome; or * peripheral white blood cell count \< 1,000 cells/mm3 as the result of myeloablative therapy or receipt of myeloablative therapy within the previous 14 days; or * known allergy to gm-csf; or * known pregnancy; or * lactating females; or * receipt of anakinra or gm-csf within the previous 28 days; or * resolution of mods by mods day 2; or * previous enrollment in the grace-2 study.
effect of phytoecdysterone administration in subjects with prediabetes

Conditions: PreDiabetes

Summary: prediabetes is the term used for people whose glucose levels do not meet the criteria for diabetes but are too high to be considered normal. this is defined by the presence of blood glucose between 100-125 mg / dl, values per glucose tolerance curve of 140-199mg / dl and/or hba1c 5.7-6.4%. prediabetes should not be considered as a clinical entity in itself, but as a risk factor for diabetes and cardiovascular disease (cvd). prediabetes is associated with obesity (especially abdominal or visceral obesity), dyslipidemia with elevated triglycerides and/or low hdl cholesterol, and hypertension.

subjects with a diagnosis of prediabetes are included according to the criteria of the american diabetes association in its version 2019, between 30 and 60 years old residents of the city of guadalajara, jalisco, mexico who come to clinical nutrition consultation in the university hospital fray antonio alcalde from the city of guadalajara, jalisco, mexico. the study design is a randomized, randomized clinical trial with a control group in two groups: an intervention group with ecdysterone 300mg every 24 hours for 12 weeks (approximately 90 days) and an approved placebo control group (magnesia stearate) ) at 300mg every 24 hours for 12 weeks (approximately 90 days).

Eligibility criteria:
inclusion criteria: 1. - fasting plasma glucose between 100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l) 2. - oral glucose tolerance test 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l) 3. - a1c 5.7-6.4% (39-47 mmol/mol). 4. - body mass index \>25 kg/m2 or \>23 kg/m2 5. - adults who have one or more of the following risk factors: * first-degree relative with diabetes * high-risk race/ethnicity * history of cvd 6. - blood pressure \<140/90 mmhg without therapy for hypertension 7. - hdl cholesterol level \ 0.250 mg/dl (2.82 mmol/l) exclusion criteria: 1.- pregnant women or lactic period 2- patients with some other chronic degenerative disease like diabetes mellitus 2 with pharmacologic treatment. 3.- hypertension 4.- cancer, 5.- hyperthyroidism 6.- hypothyroidism 7.- immunologic disease 8.- kidney disease 9.- hepatic disease 10.- cardiovascular disease 11- abaqus activity 12.-alcoholic activity.

Keywords: prediabetes ecdysterone genotoxicity citotoxicity micronuclei glycemic control
nurse vs general practitioner care for patients requesting same day consultations in primary care

Conditions: Acute Disease; Nursing Care; Ambulatory Care; Family Practice

Summary: the purpose of this study is to compare the effectiveness of nursing care in relation to usual medical care in adult patients who demand to be visited the same day in primary care teams in catalonia, as it is suggested in other countries.

the primary care demand is rapidly growing and the family physicians feel overflowed by the demand and their capacity to solve things is limited by lack of time. many organizational interventions have been planned to solve this problem. one of these is to imply the nurse professional to solve and control health problems that traditionally were the doctor's job. so, to demonstrate the nursing care is as effective as the medical care, we will compare, among both collectives, the 'quality' of care received by patients who ask an appointment for the same day.

Eligibility criteria:
inclusion criteria: * patients requesting same day consultations in primary care * assigned to the practice exclusion criteria: * do not want to participate * difficulties to follow-up * serious illness that makes the intervention impossible * home visits

Keywords: health services research nurse practitioners outcome and process assessment (health care) patient acceptance of health care patient satisfaction primary health care professional autonomy